genomic landscape associated with a novel Fc-engineered anti-CTLA-4 antibody (botensilimab) in patients with advanced solid tumors
RNA from formalin-fixed paraffin-embedded (FFPE) tumor biopsies and matched normal blood samples were isolated and subjected to RNA-sequencing using the Personalis ImmunoID NeXT Platform.